

Image

1642

PATENT

Case Docket No. MAXIM.026C3

Date: February 19, 2004


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Hellstrand et al.
Appl. No. : 10/076,306
Filed : February 12, 2002
For : ENHANCED ACTIVATION OF
NATURAL KILLER CELLS
USING AN NK CELL
ACTIVATOR AND A
HYDROGEN PEROXIDE
SCAVENGER OR INHIBITOR
Examiner : Holleran, A.L.
Group Art Unit : 1642

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

February 19, 2004

(Date)


Mallery K. de Merlier, Reg. No. 51,609


TRANSMITTAL LETTER


Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application are:

- (X) An Information Disclosure Statement.
- (X) A PTO Form 1449 with four (4) references.
- (X) The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.
- (X) Return prepaid postcard.


Mallery K. de Merlier
Registration No. 51,609
Attorney of Record
Customer No. 20,995
(619) 235-8550



INFORMATION DISCLOSURE STATEMENT

Applicant : Hellstrand et al.
App. No. : 10/076,306
Filed : February 12, 2002
For : ENHANCED ACTIVATION OF
NATURAL KILLER CELLS USING AN
NK CELL ACTIVATOR AND A
HYDROGEN PEROXIDE SCAVENGER
OR INHIBITOR
Examiner : Holleran, Anne L.
Group Art Unit : 1642

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed is form PTO-1449 listing 4 references that are also enclosed.

This Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits, and presumably no fee is required in accordance with 37 C.F.R. § 1.97(b)(3). If a first Office Action on the merits was mailed before the mailing date of this Statement, the Commissioner is authorized to charge the fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 11-1410.

Respectfully submitted,


KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 2/19/04

By: Mallory K. de Merlier

Mallory K. de Merlier
Registration No. 51,609
Attorney of Record
Customer No. 20,995
(619) 235-8550

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. MAXIM.026C3	APPLICATION NO. 10/076,306
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)		APPLICANT Hellstrand et al.	
		FILING DATE February 12, 2002	GROUP 1642



U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
	1	Bacon et al. (1995) Interleukin 12 (IL-12) induces tyrosine phosphorylation of JAK2 and TYK2: differential use of Janus family tyrosine kinases by IL-2 and IL-12. Journal of Experimental Medicine. 181:399-404.
	2	Nelson et al. (1998) Biology of the interleukin-2 receptor. Advances in Immunology. 70:1-81.
	3	Presky et al. (1996) A functional interleukin 12 receptor complex is composed of two β -type cytokine receptor subunits. Proc. Natl. Acad. Sci. 93:14002-14007.
	4	Wolf et al. (1991) Cloning of cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biologic effects on T and natural killer cells. Journal of Immunology. 146(9):3074-3081.

S:\DOCS\MKD\MKD-4082.DOC\021904

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	